SH2 and PTB domain interactions in tyrosine kinase signal transduction

Current Opinion in Chemical Biology

Volumn 1, Issue 2, 1997, Pages 227-234

  Shoelson, Steven E ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE;

DRUG DESIGN; ENZYME ACTIVATION; HUMAN; METABOLISM; REVIEW; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN;

DRUG DESIGN; ENZYME ACTIVATION; HUMANS; PHOSPHOTYROSINE; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS;

EID: 0031197193     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(97)80014-2     Document Type: Article

References (63)

1. Pawson T: Protein modules and signalling networks. Nature 1995, 373:573-580.
2. Cohen GB, Ren R, Baltimore D: Modular binding domains in signal transduction proteins. Cell 1995, 80:237-248.
3. Sudol M: The WW module competes with the SH3 domain? Trends Biochem Sci 1996, 21:161-163.
4. Songyang Z, Fanning AS, Fu C, Xu J, Marfatia SM, Chishti AH, Crompton A, Chan AC, Anderson JM, Cantley LC: Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 1997, 275:73-77.
5. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, King F, Roberts T, Ratnofsky S, Lechleider RJ, Neel BG et al.: SH2 domains recognize specific phosphopeptide sequences. Cell 1993, 72:767-778.
6. Songyang Z, Shoelson SE, McGlade J, Olivier JP, Pawson T, Bustelo XR, Barbacid M, Sabe H, Hanafusa H, Yi T et al.: Specific motifs recognized by the SH2 domains of Csk 3BP2, fps/fes, Grb-2, HCP, SHC, Syk and Vav. Mol Cell Biol 1994, 14:2777-2785.
7. Domchek SM, Auger KR, Chatterjee S, Burke TR, Shoelson SE: Inhibition of SH2 domain-phosphoprotein association by a nonhydrolyzable phosphonopeptide. Biochemistry 1992, 31:9865-9870.
8. Piccione E, Case RD, Domchek SM, Hu P, Chaudhuri M, Backer JM, Schlessinger J, Shoelson SE: PI 3-kinase p85 SH2 domains specificity defined by direct phosphopeptide/SH2 domain binding. Biochemistry 1993, 32:3197-3202.
9. Case RD, Piccione E, Wolf G, Bennett AM, Lechleider RJ, Neel BG, Shoelson SE: SH-PTP2/Syp SH2 domain specificity defined by direct interactions with PDGF-receptor, EGF receptor and IRS-1 derived phosphopeptides. J Biol Chem 1994, 269:10467-10474.
10. Ladbury JE, Lemmon MA, Zhou M, Green J, Botfield MC, Schlessinger J: Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal. Proc Natl Acad Sci USA 1995, 92:3199-3203.
11. Lee C-H, Kominos D, Jaques S, Margolis B, Schlessinger J, Shoelson SE, Kuriyan J: Crystal structures of peptide complexes of the N-terminal SH2 domain of the Syp tyrosine phosphatase. Structure 1994, 2:423-438.
12. Pascal SM, Singer AU, Gish G, Muhandiram R, Yamazaki T, Shoelson SE, Pawson T, Kay LE, Forman-Kay JD: Nuclear magnetic resonance structure of an SH2 domain of PLC complexed with a high affinity binding peptide. Cell 1994, 77:461-472.
13. Kuriyan J, Cowburn D: Modular peptide recognition domains in eukaryotic signaling. Annu Rev Biophys Biomol Struct 1997, in press. An in-depth review of the structures of modular domains, including SH2 and PTB domains.
14. Waksman G, Shoelson SE, Pant N, Cowburn D, Kuriyan J: Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell 1993, 72:779-790.
15. lck. Nature 1993, 362:87-91.
16. Nolte R, Eck MJ, Schlessinger J, Shoelson SE, Harrison SC: Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes. Nat Struct Biol 1996, 3:364-374.
17. Hall H, Williams EJ, Moore SE, Walsh FS, Prochiantz A, Doherty P: Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neurite outgrowth by a cell-membrane permeable phosphopeptide. Curr Biol 1996, 6:580-587. A transmembrane peptide was coupled to an SH2 domain-binding peptide to study the effects of SH2 domain inhibition.
18. Rojas M, Yao SY, Lin YZ: Controlling EGF-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 1996, 271:27456-27461, A signal peptide sequence was coupled to an SH2 domain binding peptide to study the effects of SH2 domain inhibition.
19. Burke TR, Smyth MS, Otaka A, Nozimu M, Roller PP, Wolf G, Case R, Shoelson SE: Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase resistant SH2 domain inhibitors. Biochemistry 1994, 33:6490-6494.
20. Ye B, Akamatsu M, Shoelson SE, Wolf G, Giorgetti-Peraldi S, Van X, Roller P, Burke TR: L-O-(2-Malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides. J Med Chem 1995, 38:4270-4275.
21. Burke TR Jr, Ye B, Akamatsu M, Ford H, Yan X, Kole HK, Wolf G, Shoelson SE, Roller PP: 4-O-[2-(2-Fluoromalonyl)]-L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides. J Med Chem 1996, 39:1021-1027.
22. Chuang LM, Myers MG, Backer JM, Shoelson SE, White MF, Birnbaum MJ, Kahn CR: Insulin-stimulated oocyte maturation requires insulin receptor substrate 1 and interaction with the SH2 domains of phosphatidylinositol 3-kinase. Mol Cell Biol 1993, 13:6653-6660.
23. Xiao S, Rose DW, Sasoka T, Maegawa H, Burke TR, Roller PP, Shoelson SE, Olefsky JM: Syp/SH-PTP2 is a positive mediator of growth factor stimulated mitogenic signal transduction. J Biol Chem 1994, 269:21244-21248.
24. 2-TAM zeta 3, a novel competitive inhibitor of the binding of ZAP-70 to the T cell antigen receptor, blocks early T cell signaling. J Biol Chem 1995, 270:944-948.
25. Kotani K, Yonezawa K, Hara K, Ueda H, Kitamura Y, Sakaue H, Ando A, Chavanieu A, Calas B, Grigorescu F et al.: Involvement of phosphoinositide 3-kinase in insulin- or IGF-1-induced membrane ruffling. EMBO J 1994, 13:2313-2321.
26. Eck MJ, Pluskey S, Trub T, Harrison SC, Shoelson SE: Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Nature 1996, 379:277-280. Comparisons between structure of tandem SH2 domains shows that orientations of peptide binding sites are distinct. These findings suggest that specificity in signaling may be due in part to limitations on the potential orientations that tandem domains might adopt.
27. Rahuel J, Gay B, Erdmann D, Strauss A, Garcia-Echeverria C, Furet P, Caravatti G, Fretz H, Schoepfer J, Grutter MG: Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode. Nat Struct Biol 1996, 3:586-589.
28. ••] structure-based approaches are being successfully applied to generate SH2 domain inhibitors from peptide leads.
29. Sharipour A, Plummer MS, Lunney EA, Para KS, Stankovic CJ, Rubin JR, Humblet C, Fergus JH, Marks JS, Herrara R et al.: Novel phosphotyrosine mimetics in the design of peptide ligands for pp60src SH2 domain. Bioorg Med Chem Lett 1996, 6:1209-1214.
30. ••].
31. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW: Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534. A novel approach to drug discovery. Low affinity ligands are identified by changes in NMR spectra. Higher affinity 'leads' can be generated by covalent linkage of two or more low affinity ligands.
32. Kavanaugh WM, Williams LT: An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. Science 1994, 266:1862-1865.
33. Blaikie P, Immanuel D, Wu J, Li N, Yajnik V, Margolis B: A region in She distinct from the SH2 domain can bind tyrosine-phosphorylated growth factor receptors. J Biol Chem 1994, 269:32031-32034.
34. O'Neill TJ, Craparo A, Gustafson TA: Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two-hybrid system. Mol Cell Biol 1994, 14:6433-6442.
35. Wolf G, Trub T, Ottinger E, Groninga L, Lynch A, White M, Miyazaki M, Lee J, Shoelson SE: The PTB domains of IRS-1 and She have distinct but overlapping binding specificities. J Biol Chem 1995, 270:27407-27410.
36. Trub T, Choi WE, Wolf G, Ottinger E, Chen Y, Weiss MA, Shoelson SE: Specificity of the PTB domain of She for turn-forming pentapeptide motifs ammo-terminal to phosphotyrosine. J Biol Chem 1995, 270:18205-18208.
37. Dikic I, Batzer AG, Blaikie P, Obermeier A, Ullrich A, Schlessinger J, Margolis B: She binding to nerve growth factor receptor is mediated by phosphotyrosine interaction domain. J Biol Chem 1995, 270:15125-15129.
38. Bork P, Margolis B: A phosphotyrosine interaction domain. Cell 1995, 80:693-694.
39. Borg J-P, Ooi J, Levy E, Margolis B: The phosphotyrosine interaction domains of X11 and Fe65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Mol Cell Biol 1996, 16:6229-6241. Phosphotyrosine-independent binding by a phosphotyrosine binding domain.
40. Sun XJ, Wang L-M, Zhang Y, Yenush L, Myers MG, Glasheen E, Lane WS, Pierce JH, White MF: Role of IRS-2 in insulin and cytokine signalling. Nature 1995, 377:173-177.
41. Lavan BE, Lane WS, Lienhard GE: The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J Biol Chem 1997, 272:11439-11443.
42. Yamanashi Y, Baltimore D: Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein Dok. Cell 1997, 88:205-212.
43. Zhou M-M, Ravichandran KS, Olejniczak ET, Petros AM, Meadows RP, Harlan JE, Wade WS, Burakoff SJ, Fesik SW: Structure and ligand recognition of the phosphotyrosine binding domain of Shc. Nature 1995, 378:584-592.
44. Eck MJ, Dhe-Paganon S, Trub T, Nolte R, Shoelson SE: Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. Cell 1996, 85:695-705. Structure of the insulin receptor (IRS-1) phosphotyrosine binding domain bound to an insulin receptor juxtamembrane domain peptide.
45. Zhou M-M, Huang B, Olejniczak ET, Meadows RP, Shuker SB, Miyazaki M, Trub T, Shoelson SE, Fesik SW: Structural basis for IL-4 receptor phosphopeptide recognition by the IRS-1 PTB domain. Nat Struct Biol 1996, 3:388-393. Structure of the insulin receptor (IRS-1) PTB domain bound to the interleukin-4 receptor peptide.
46. Harlan JE, Hajduk PJ, Yoon HS, Fesik SW: Pleckstrin homology domains bind to phosphatidylinositol 4,5-bisphosphate. Nature 1994, 371:168-170.
47. Ferguson KM, Lemmon MA, Schlessinger J, Sigler PB: Structure of the high affinity complex of inositol triphosphate with a PLC pleckstrin homology domain. Cell 1995, 83:1037-1046.
48. Hyvonen M, Macias MJ, Nilges M, Oschkinat H, Saraste M, Wilmanns M: Structure of the binding site for inositol phosphates in a PH domain. EMBO J 1995, 14:4676-4685.
49. Van der Geer P, Wiley W, Lai VK-M, Olivier JP, Gish GD, Stephens R, Kaplan D, Shoelson SE, Pawson T: A conserved aminoterminal Shc domain binds to phosphotyrosine motifs in activated growth factor receptors and phosphopeptides. Curr Biol 1995, 5:404-412.
50. Songyang Z, Margolis B, Chaudhuri M, Shoelson SE, Cantley LC: The phosphotyrosine interaction domain of She recognizes tyrosine-phosphorylated NPXY motif. J Biol Chem 1995, 270:14863-14866.
51. Kavanaugh WM, Turck CW, Williams LT: PTB domain binding to signaling proteins through a sequence motif containing phosphotyrosine. Science 1995, 268:1177-1179.
52. Ravichandran KS, Igras V, Shoelson SE, Fesik SW, Burakoff SJ: Evidence for a functional role for the PTB domain of Shc in interleukin-2 signaling. Proc Natl Acad Sci USA 1996, 93:5275-5280.
53. Giorgetti-Peraldi S, Ottinger E, Wolf G, Ye B, Burke TR, Shoelson SE: Cellular effects of PTB domain inhibitors on insulin receptor signaling and trafficking. Mol Cell Biol 1997, 17:1180-1188. Peptides that bind phosphotyrosine binding domains inhibit signaling effects in cells.
54. Ricketts WA, Rose DW, Shoelson SE, Olefsky JM: Functional roles of the Shc PTB and SH2 domains in insulin and EGF signaling. J Biol Chem 1996, 271:26165-26169.
55. •] new proteins with widely spaced TAMs for SHP-2 binding are discussed.
56. •].
57. •].
58. Carpenter CL, Auger KR, Chaudhuri M, Yoakim M, Schaffhausen B, Shoelson SE, Cantley LC: Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85 kDa subunit. J Biol Chem 1993, 268:9478-9483.
59. Herbst JJ, Andrews GC, Contillo LG, Lamphere L, Gardner JP, Lienhard GE, Gibbs M: Potent activation of phosphatidylinositol 3-kinase by simple phosphotyrosine peptides derived from insulin receptor substrate 1 containing two YMXM motifs for binding SH2 domains. Biochemistry 1994, 33:9376-9381.
60. Pluskey S, Wandless TJ, Walsh CT, Shoelson SE: Potent stimulation of SH-PTP2 phosphatase activity by IRS-1 binding to both of its SH2 domains. J Biol Chem 1995, 270:2897-2900.
61. Shiue L, Zoller MJ, Brugge JS: Syk is activated by phosphotyrosine-containing peptides representing the tyrosine-based activation motifs of the high affinity receptor for IgE. J Biol Chem 1995, 270:10498-10502.
62. Rowley RB, Burkhardt AL, Chao HG, Matsueda GR, Bolen JB: Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation. J Biol Chem 1995, 270:11590-11594.
63. Hatada MH, Lu X, Laird ER, Green J, Morgenstern JP, Lou M, Marr CS, Phillips TB, Ram MK, Theriault K et al.: Molecular basis for the interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor. Nature 1995, 377:32-38.